Rampart Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-664
Closed -$372K 295
2020
Q3
$372K Sell
664
-1,375
-67% -$834K 0.24% 104
2020
Q2
$1.27M Buy
2,039
+879
+76% +$499K 0.21% 136
2020
Q1
$566K Buy
1,160
+226
+24% +$93.2K 0.27% 82
2019
Q4
$351K Buy
934
+43
+5% +$14.5K 0.04% 369
2019
Q3
$247K Sell
891
-17
-2% -$5.03K 0.03% 403
2019
Q2
$284K Sell
908
-40
-4% -$13.3K 0.03% 398
2019
Q1
$389K Buy
948
+144
+18% +$59.3K 0.04% 354
2018
Q4
$300K Sell
804
-1,778
-69% -$651K 0.08% 208
2018
Q3
$348K Sell
2,582
-699
-21% -$266K 0.15% 152
2018
Q2
$1.13M Buy
3,281
+1,216
+59% +$380K 0.11% 252
2018
Q1
$711K Buy
2,065
+1,124
+119% +$391K 0.07% 290
2017
Q4
$354K Sell
941
-98
-9% -$39.7K 0.14% 173
2017
Q3
$465K Buy
1,039
+56
+6% +$26.6K 0.16% 152
2017
Q2
$483K Buy
983
+775
+373% +$339K 0.17% 133
2017
Q1
$81K Sell
208
-1,251
-86% -$464K 0.03% 178
2016
Q4
$536K Sell
1,459
-5
-0.3% -$1.9K 0.19% 94
2016
Q3
$589K Buy
+1,464
New +$587K 0.23% 87

Other funds holding REGN

Rampart Investment Management's REGN Position: Q4 2020 in Review

Rampart Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 664 shares — an estimated $372K sold.

Rampart Investment Management first reported a position in REGN in Q3 2016 and held it in 17 quarters. The position peaked at $1.27M in Q2 2020. 904 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Rampart Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Rampart Investment Management sold 664 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $372K.
  • Rampart Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 17 quarters.
  • Rampart Investment Management's Regeneron Pharmaceuticals position peaked at $1.27M in Q2 2020.
  • 904 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Rampart Investment Management's 13F filing for Q4 2020.